Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How ONC201 is Taken Orally with Minimal Side Effects. Clinical…
Browsing: Acute Lymphoblastic Leukemia
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How Patients Must Have Progressive Disease after 1st Line of…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains Phase 2 Clinical Trial of ONC201 in Patients with Glioma…
Andrew Chi, MD, PhD at NYU Langone Medical Center explains how K27M Mutations are Rare within Gliomas, an Already Rare…
Andrew Chi, MD, PhD at NYU Langone Medical Center explains how ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine…
Presented by Aziz Nazha, MD. Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60%…
Presented by Ehab Atallah, MD. There is a significant unmet need in existing treatment paradigms for patients with acute myeloid…
Immunotherapy has the potential to provide long-term benefits to certain lung cancer patients; however, certain patients may not respond, while…
Informal carers play an essential role in the care of many lung cancer patients. Here, Morag Farquhar, PhD, of the…
Breathlessness is a frightening and disabling symptom of lung cancer; therefore, it is vital that patients, carers, family and healthcare…
Breathlessness is a scary symptom for lung cancer patients and their family, who often act as informal carers. Speaking from…
Patient advocacy, by individuals and organizations, serves an imperative role in healthcare, giving a voice to those who are most…
The neuroendocrine tumor (NET) Patient Foundation is a valuable resource for patients with NETs, as well as their carers. Here,…
CAR T-cells are an exciting therapeutic area, which although promising are still in the early stages of development for solid…
There are numerous ongoing and planned clinical trials investigating immuno-oncology (IO) agents for lung cancer, particularly in combination with other…
For lung cancer, early diagnosis and staging is crucial to survival. However, the length of the lung cancer pathway differs…
Exciting clinical trial updates were presented at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.…
In the coming era of lung cancer management, where the use of both targeted agents and new immunotherapies seems extremely…
A key subject on everyones mind at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland,…
The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, hosted sessions covering a diverse range of…
This is an exciting time for research into the early diagnosis of lung cancer, with a number of promising options…
There is a growing need to improve the early diagnosis of lung cancer; non-invasive, quick and accessible assays would greatly…
A non-invasive biomarker assay to detect lung cancer would be ideal; avoiding needless biopsies and providing another step of diagnostic…
One issue with lung cancer screening is that nodules, which may or may not be malignant, can be detected, leading…
With rapid advancements in the management of lung cancer, new questions and challenges undoubtedly arise. Here, James Spicer, PhD, FRCP,…
As explained here by James Spicer, PhD, FRCP, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, the field…
As our understanding of the different oncogenes that serve a role in the pathogenesis of lung cancer increases, so does…
Lung cancer screening is an exciting and greatly debated topic in the UK; on one hand it could greatly improve…
Lung cancer management in the UK is on the pinnacle of great change, with the current implementation of the National…
The National Optimal Lung Cancer Pathway (NOLCP), a hugely accelerated new lung cancer care pathway in the UK, was a…
Tobacco use is a major determinant of lung cancer risk; therefore, it is vital that a patients smoking status and…
The National Optimal Lung Cancer Pathway (NOLCP), a streamlined care pathway to improve the speed of lung cancer diagnosis, staging…
The past several years have been extremely exciting in the field of bladder cancer, with checkpoint inhibitors emerging as efficacious…
The 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, hosted an exciting Best of Journals session, highlighting key research…
Despite there now being a variety of promising immunotherapies for bladder cancer, a large proportion of patients dont respond to…
Ashkan Lashkari, MD, shares Dr. Kesari on Neuro-Oncology Some patients do well if given treatments in neoadjuvantat the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Fakih’s Talk on Colorectal Cancer Microsatellite instability is an approved biomarker at the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Hurvitzs Study on Breast Cancer Using Tumor-Infiltrating Lymphocytes as a biomarker at the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Reckcamp Overview on Lung Cancer Combine established Immunotherapy with new therapies at the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Hamid On Metastatic Melanoma IDO Inhibitors can help overcome resistance at the 2018 Oncology Summit…
Ashkan Lashkari, MD, shares Dr. Powells Study On RCC & Bladder Tumors Augment treatment responses with good safety signals at…
Ashkan Lashkari, MD, gives a MOASC Overview – Highlights from Presentations A number of speakers talk across different tumor types…
Santosh Kesari, MD, explains Looking Forward to Mature Data on Glioblastoma Updates from Antibody-based trials at the 2018 Oncology Summit…
Santosh Kesari, MD, explains Patients May Benefit from Molecular Profiling of Tumor BRAF, PI3K, etc, would benefit from available drugs…
Santosh Kesari, MD, discusses how Immunotherapy Can have Activity in the Brain Do better at managing toxicities at the 2018…
Santosh Kesari, MD, Immunotherapy in Glioma Study in the neoadjuvant setting at the 2018 Oncology Summit in Huntington Beach, CA…
There was exciting news in the field of bladder cancer treatment at the 2018 Genitourinary Cancers Symposium, held in San…
Whether or not patients with prostate cancer with adverse pathological features (APF) following radical prostatectomy should be offered radiotherapy immediately…
Patients with oligometastatic prostate cancer can be identified using highly advanced detection tools, such as positron emission tomography (PET) and…
Bladder preservation remains a viable option for certain patients with bladder cancer; with previous studies showing that patients up to…